2 citations
,
May 2017 in “Journal of the American Academy of Dermatology” Tofacitinib helped a 19-year-old regrow hair after other treatments failed.
August 2024 in “JAAD Case Reports” Upadacitinib successfully regrew hair in a child with alopecia universalis and specific genetic mutations.
29 citations
,
January 2003 in “Dermatology” The condition called 'acute diffuse and total alopecia of the female scalp' is actually a known condition named alopecia areata incognita.
June 2024 in “Military medicine” JAK inhibitors like baricitinib and ritlecitinib are effective new treatments for severe alopecia areata.
April 2021 in “Journal of Investigative Dermatology” An AI photographic device effectively tracked hair growth improvements in women treated for hair loss.
1 citations
,
October 2025 in “Journal of Allergy and Clinical Immunology” A JAK1 variant causes hair loss, skin issues, and thyroid disease, but treatment with a specific inhibitor can help.
42 citations
,
April 2021 in “Journal of clinical pharmacology” Baricitinib helps treat several diseases, including COVID-19, but has side effects and needs careful monitoring.
2 citations
,
July 2004 in “Proceedings of SPIE, the International Society for Optical Engineering/Proceedings of SPIE” Near-infrared laser therapy with Indocyanine Green dye improves acne by reducing inflammation without side effects.
January 2009 in “Journal of Zhengzhou University” LAIC cream can improve acne by making skin thinner and softer.
January 2026 in “Clinical Cosmetic and Investigational Dermatology” Early diagnosis and targeted anti-inflammatory treatments can improve outcomes in androgenetic alopecia with perifollicular inflammation and fibrosis.
June 2025 in “Korean Journal of Pharmacognosy” Isoalantolactone promotes hair growth by activating specific cell pathways.
3 citations
,
July 2025 in “Clinical and Experimental Dermatology” Ritlecitinib may be more effective for severe alopecia areata than conventional treatments.
December 2024 in “Research Journal of Medical Sciences” Injectable Platelet Rich Fibrin effectively improves hair growth in males with hair loss.
Baricitinib is more effective than methotrexate for severe alopecia areata.
March 2026 in “Immunological Medicine” Janus kinase inhibitors help some people with severe alopecia areata regrow hair, but not everyone responds, and relapses can happen.
February 2025 in “Archives of Dermatological Research” Injectable platelet-rich fibrin effectively improves hair density and scalp symptoms in androgenetic alopecia.
2 citations
,
September 2022 in “Dermatologic Therapy” Tofacitinib is a promising treatment for severe alopecia areata, with many patients experiencing complete or partial hair regrowth.
January 2026 in “DOAJ (DOAJ: Directory of Open Access Journals)” Early biopsy and targeting inflammation can improve treatment for hair loss in androgenetic alopecia.
7 citations
,
July 2024 in “Dermatology Practical & Conceptual” SII is a useful and affordable tool to assess and monitor alopecia areata.
September 2024 in “Journal of the European Academy of Dermatology and Venereology” Baricitinib effectively reduces hair loss in severe alopecia areata with mild side effects.
The I National Academic Congress of Dermatology in 2021 expanded to include participants from across Brazil and discussed dermatology topics, including COVID-19.
38 citations
,
September 2017 in “Journal of zoo and wildlife medicine” Oclacitinib maleate successfully treated alopecia in Andean bears.
1 citations
,
July 2018 in “Elsevier eBooks” FAPD and possibly CCCA may be AGA subtypes, and treatments combining antiandrogens, hair growth agents, hair transplants, and anti-inflammatories could be effective.
5-ARI therapy may help prevent prostate cancer progression.
June 2020 in “Zenodo (CERN European Organization for Nuclear Research)” Children with frequent severe infections and low antibodies should be checked for immune deficiencies.
April 2023 in “Journal of Investigative Dermatology” Contact immunotherapy can change immune responses in alopecia areata, suggesting new treatment targets.
August 2024 in “Clinical Cosmetic and Investigational Dermatology” Upadacitinib and narrowband UVB effectively treated a child's vitiligo and alopecia areata.
December 2025 in “Journal of Human Immunity” JAK inhibitors may help improve symptoms in adults with APECED.
2 citations
,
March 2025 in “Journal of Translational Autoimmunity” Targeting the AhR pathway may help treat alopecia areata.
January 2017 in “IMC Journal of Medical Science” A rare endocrine disorder, APS 1, was diagnosed in a 26-year-old man in Bangladesh.